Pharmacokinetics and placental transfer of single-dose tenofovir 1% vaginal gel in term pregnancy

Richard Beigi, Lisa Noguchi, Teresa Parsons, Ingrid Macio, Ratiya P. Kunjara Na Ayudhya, Jianmeng Chen, Craig W. Hendrix, Benoît Mâsse, Megan Valentine, Jeanna Piper, D. Heather Watts

Research output: Contribution to journalArticle

Abstract

Tenofovir (TFV) 1% vaginal gel has been found to decrease sexual transmission of human immunodeficiency virus. To initiate investigations during pregnancy, 16 healthy pregnant women scheduled for cesarean delivery received a single application of TFV gel preoperatively. Maternal serum drug concentrations were determined and fetal cord blood, amniotic fluid, placental tissue, and endometrial tissue specimens were collected. The median maternal peak concentration and cord blood TFV concentrations were 4.3 and 1.9 ng/mL, respectively (∼100-and 40-fold lower than after TFV oral dosing, respectively). No adverse events were related to the use of TFV gel. These findings support ongoing and future investigations of TFV gel in pregnancy.

Original languageEnglish (US)
Pages (from-to)1527-1531
Number of pages5
JournalJournal of Infectious Diseases
Volume204
Issue number10
DOIs
StatePublished - Nov 15 2011

    Fingerprint

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Cite this

Beigi, R., Noguchi, L., Parsons, T., Macio, I., Kunjara Na Ayudhya, R. P., Chen, J., Hendrix, C. W., Mâsse, B., Valentine, M., Piper, J., & Watts, D. H. (2011). Pharmacokinetics and placental transfer of single-dose tenofovir 1% vaginal gel in term pregnancy. Journal of Infectious Diseases, 204(10), 1527-1531. https://doi.org/10.1093/infdis/jir562